$FOLD,
Amicus Therapeutics Inc. (FOLD) Trading 10.2% Higher on Insider Buying Activity
Posted by Eileen French on Dec 25th, 2016 // No Comments
Amicus Therapeutics logoAmicus Therapeutics Inc. (NASDAQ:FOLD) shares traded up 10.2% during trading on Friday after an insider bought additional shares in the company. The company traded as high as $5.01 and last traded at $4.99, with a volume of 3,655,041 shares trading hands. The stock had previously closed at $4.53.
Specifically, major shareholder Perceptive Advisors Llc acquired 189,500 shares of the firm’s stock in a transaction on Thursday, December 22nd. The stock was acquired at an average cost of $4.51 per share, for a total transaction of $854,645.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Hung Do sold 25,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $7.00, for a total transaction of $175,000.00. Following the sale, the insider now owns 533,453 shares of the company’s stock, valued at $3,734,171. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
FOLD has been the subject of several research reports. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 23rd. Leerink Swann restated a “buy” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. Robert W. Baird restated a “hold” rating and set a $7.00 price objective (down from $9.00) on shares of Amicus Therapeutics in a research note on Tuesday, November 29th. Cowen and Company restated an “outperform” rating and set a $12.00 price objective (down from $15.00) on shares of Amicus Therapeutics in a research note on Wednesday, November 30th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $11.00 price objective (down from $12.00) on shares of Amicus Therapeutics in a research note on Wednesday, November 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $11.08.
The stock’s 50-day moving average is $6.94 and its 200-day moving average is $6.77. The stock’s market capitalization is $710.21 million.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analysts’ expectations of $1.71 million. On average, equities analysts anticipate that Amicus Therapeutics Inc. will post ($1.41) earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Pictet Asset Management Ltd. raised its position in shares of Amicus Therapeutics by 674.9% in the second quarter. Pictet Asset Management Ltd. now owns 4,707,381 shares of the biopharmaceutical company’s stock valued at $33,328,000 after buying an additional 4,099,881 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $29,750,000. Jennison Associates LLC raised its position in shares of Amicus Therapeutics by 53.6% in the third quarter. Jennison Associates LLC now owns 7,906,476 shares of the biopharmaceutical company’s stock valued at $58,508,000 after buying an additional 2,759,262 shares in the last quarter. Redmile Group LLC raised its position in shares of Amicus Therapeutics by 14.8% in the third quarter. Redmile Group LLC now owns 12,751,536 shares of the biopharmaceutical company’s stock valued at $94,361,000 after buying an additional 1,645,090 shares in the last quarter. Finally, CQS Cayman LP bought a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $7,589,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
5 Day Chart for NASDAQ:FOLD
Amicus Therapeutics Inc. (FOLD) Trading 10.2% Higher on Insider Buying Activity
Posted by Eileen French on Dec 25th, 2016 // No Comments
Amicus Therapeutics logoAmicus Therapeutics Inc. (NASDAQ:FOLD) shares traded up 10.2% during trading on Friday after an insider bought additional shares in the company. The company traded as high as $5.01 and last traded at $4.99, with a volume of 3,655,041 shares trading hands. The stock had previously closed at $4.53.
Specifically, major shareholder Perceptive Advisors Llc acquired 189,500 shares of the firm’s stock in a transaction on Thursday, December 22nd. The stock was acquired at an average cost of $4.51 per share, for a total transaction of $854,645.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Hung Do sold 25,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $7.00, for a total transaction of $175,000.00. Following the sale, the insider now owns 533,453 shares of the company’s stock, valued at $3,734,171. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
FOLD has been the subject of several research reports. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 23rd. Leerink Swann restated a “buy” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. Robert W. Baird restated a “hold” rating and set a $7.00 price objective (down from $9.00) on shares of Amicus Therapeutics in a research note on Tuesday, November 29th. Cowen and Company restated an “outperform” rating and set a $12.00 price objective (down from $15.00) on shares of Amicus Therapeutics in a research note on Wednesday, November 30th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $11.00 price objective (down from $12.00) on shares of Amicus Therapeutics in a research note on Wednesday, November 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $11.08.
The stock’s 50-day moving average is $6.94 and its 200-day moving average is $6.77. The stock’s market capitalization is $710.21 million.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analysts’ expectations of $1.71 million. On average, equities analysts anticipate that Amicus Therapeutics Inc. will post ($1.41) earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Pictet Asset Management Ltd. raised its position in shares of Amicus Therapeutics by 674.9% in the second quarter. Pictet Asset Management Ltd. now owns 4,707,381 shares of the biopharmaceutical company’s stock valued at $33,328,000 after buying an additional 4,099,881 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $29,750,000. Jennison Associates LLC raised its position in shares of Amicus Therapeutics by 53.6% in the third quarter. Jennison Associates LLC now owns 7,906,476 shares of the biopharmaceutical company’s stock valued at $58,508,000 after buying an additional 2,759,262 shares in the last quarter. Redmile Group LLC raised its position in shares of Amicus Therapeutics by 14.8% in the third quarter. Redmile Group LLC now owns 12,751,536 shares of the biopharmaceutical company’s stock valued at $94,361,000 after buying an additional 1,645,090 shares in the last quarter. Finally, CQS Cayman LP bought a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $7,589,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
5 Day Chart for NASDAQ:FOLD
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
